The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant lazertinib with or without chemotherapy for patients with epidermal growth factor receptor (EGFR)-mutated resectable non-small cell lung cancer (NSCLC): NeoLazer trial.
 
Hye Ryun Kim
Honoraria - AstraZeneca; MSD Oncology
Consulting or Advisory Role - AstraZeneca; BeiGene
Speakers' Bureau - ABL Bio; AstraZeneca; MSD Oncology; Ono Pharmaceutical; Roche/Genentech; Yuhan
Research Funding - AstraZeneca (Inst); Yuhan (Inst)
 
Se-Hoon Lee
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol Myers Squibb Foundation; Lilly; Merck Sharp & Dohme; Roche; Yuhan
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; BMS/Ono; Daiichi Sankyo; IMBdx; ImmuneOncia; Janssen; Lilly; Merck (German); Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Abion
Research Funding - AstraZeneca (Inst); Daiichi Sankyo; Lunit (Inst); Merck Sharp & Dohme (Inst)
 
Se Hyun Kim
Consulting or Advisory Role - Pfizer; Takeda
 
Min Hee Hong
Stock and Other Ownership Interests - GI biome; GI cell
Honoraria - AstraZeneca; BeiGene; Merck; Roche
Consulting or Advisory Role - AstraZeneca; BeiGene; Daiichi Sankyo/Astra Zeneca; Merck; Roche; Yuhan
Research Funding - Yuhan
 
Chang Gon Kim
Honoraria - Boryung
Consulting or Advisory Role - Amgen; Johnson & Johnson/Janssen; Novartis; Ono Pharmaceutical; Pfizer
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Dong-A ST; Hanmi; Merck; MSD Oncology; Novartis; Takeda
Research Funding - Ipsen
 
Ha Eun Kim
No Relationships to Disclose
 
Myung-Ju Ahn
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN
Consulting or Advisory Role - Alpha pharmaceutical; Amgen; Arcus Ventures; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN
Research Funding - YUHAN
 
Jin Seok Ahn
Honoraria - Amgen; AstraZeneca; Bayer; BC World Pharmaceutical; Boehringer Ingelheim; Boryung; Kyowa Kirin; Lilly; Menarini; Nokwon Medical; Novartis; Pfizer; Roche; Samyang; Takeda; Yuhan
Consulting or Advisory Role - Daiichi Sankyo Korea; Guardant Health; ImmuneOncia; Pharmbio Korea; Roche; Therapex; Yuhan
 
Sehhoon Park
No Relationships to Disclose
 
Seong Yong Park
No Relationships to Disclose
 
Jong Ho Cho
No Relationships to Disclose
 
Junghee Lee
No Relationships to Disclose
 
Yeong Jeong Jeon
No Relationships to Disclose
 
Yu Jung Kim
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Bridge Biotherapeutics (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Hong Kwan Kim
No Relationships to Disclose
 
Chang Young Lee
No Relationships to Disclose